Lv65
2220 积分 2021-02-15 加入
BAFF/APRIL-targeted therapy for systemic lupus erythematosus and lupus nephritis: a systematic review and meta-analysis
1小时前
已完结
The Association of Proteinuria Target Achievement Timing and Stability with Adverse Kidney Outcomes among Patients with IgA Nephropathy: A Cohort Study
2天前
已完结
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
6天前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
17天前
已完结
Research Progress on Membranous Nephropathy-Related Antigens and Immune-Targeted Therapy
1个月前
已完结
Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series
2个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
2个月前
已完结
Atrasentan in Patients with IgA Nephropathy
2个月前
已完结
Iptacopan in IgA Nephropathy — Final 24-Month Data
2个月前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
2个月前
已完结
皖公网安备34019202002308
